Top

Published in:

01-09-2015 | Original Scientific Report

Preoperative Platelet–Lymphocyte Ratio Augments CA 19-9 as a Predictor of Malignancy in Chronic Calcific Pancreatitis

Authors: Ashwin Rammohan, Sathya D. Cherukuri, Ravichandran Palaniappan, Senthil Kumar Perumal, Jeswanth Sathyanesan, Manoharan Govindan

Published in: World Journal of Surgery | Issue 9/2015

Abstract

Introduction

Differentiating inflammatory from malignant head mass in the background of chronic calcific pancreatitis (CCP) is difficult, and there is no investigation which can reliably solve this dilemma. An accurate diagnosis is crucial as the treatment is different for the two cases and a failure to identify malignancy before surgery can be disastrous. We aimed to assess the accuracy of platelet–lymphocyte ratio (PLR) and to compare it with CA 19-9 in determining the nature of pancreatic head mass (PHM).

Materials and methods

Eighty-three patients, who presented with CCP and PHM between 2005 and 2011, were included in the study. Patients identified to have malignancy underwent pancreaticoduodenectomy, while those deemed to have a benign lesion underwent Frey’s procedure. Clinical features of both the groups were compared. CA 19-9 and PLR individually and in combination were compared in both groups. Receiver operating characteristic curves were used to analyze the predictive values of CA 19-9 and PLR individually and together.

Results

Histologically, 66.3 % had an inflammatory head mass and 33.7 % had a malignant head mass. Significant clinical features which predicted a malignancy included the presence of a head mass in CCP of tropics, older age, jaundice, sudden worsening abdominal pain, gastric outlet obstruction, and significant weight loss. Sensitivity and specificity of CA 19-9 and PLR in diagnosing malignancy were similar (85.5 vs. 81.2 and 96.4 vs. 92.8 %, respectively), on combining CA 19-9 and PLR, there was an improvement in sensitivity (94.5 %).

Conclusion

PLR is at least as good as CA 19-9 as a diagnostic marker to differentiate between malignant and inflammatory head mass in CCP. When used together, PLR improves the predictive value of serum CA 19-9.

Zografos GN, Bean AG, Bowles M, Williamson RC (1997) Chronic pancreatitis and neoplasia: correlation or coincidence. HPB Surg 10:235–239. doi:10.1155/1997/89374 PubMedCentralPubMedCrossRef

Bedi MM, Gandhi MD, Jacob G, Lekha V, Venugopal A, Ramesh H (2009) CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit? Indian J Gastroenterol 28:24–27. doi:10.1007/s12664-009-0005-4 PubMedCrossRef

Perumal S, Palaniappan R, Pillai SA, Velayutham V, Sathyanesan J (2013) Predictors of malignancy in chronic calcific pancreatitis with head mass. World J Gastrointest Surg 5(4):97–103. doi:10.4240/wjgs.v5.i4.97 PubMedCentralPubMedCrossRef

Mohan V, Premalatha G, Pitchumoni CS (2003) Tropical chronic pancreatitis: an update. J Clin Gastroenterol 36:337–346. doi:10.1097/00004836-200304000-00012 PubMedCrossRef

Falconi M, Casetti L, Salvia R, Sartori N, Bettini R, Mascetta G et al (2000) Pancreatic head mass, how can we treat it? Chronic pancreatitis: surgical treatment. JOP 1:154–161PubMed

Schlieman MG, Ho HS, Bold RJ (2003) Utility of tumour markers in determining resectability of pancreatic cancer. Arch Surg 138:951–956. doi:10.1001/archsurg.138.9.951 PubMedCrossRef

Daram DR (2006) CA 19-9: not a magic marker for pancreatic cancer. South Med J 99:205. doi:10.1097/01.smj.0000204525.62861.85 PubMedCrossRef

Nouts A, Levy P, Voitot H, Bernades P (1998) Diagnostic value of serum CA 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterol Clin Biol 22:152–159. doi:GCB-03-1998-22-2-0399-8320-101019-ART72PubMed

Minghini A, Weireter LJ, Perry RR (1998) Specificity of elevated CA 19-9 levels in chronic pancreatitis. Surgery 124:103–105. doi:10.1016/S0039-6060(98)70082-0 PubMedCrossRef

10.

Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R et al (2005) Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma of the head of pancreas. Br J Cancer 92:21–23. doi:10.1038/sj.bjc.6602305 PubMedCentralPubMedCrossRef

11.

Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A (2007) Paradoxical effects of cytokines in tumor immune surveillance and tumor escape. Cytokine Growth Factor Rev 18:171–182. doi:10.1016/j.cytogfr.2007.01.015 PubMedCrossRef

12.

Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D et al (1999) Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 155:537–547. doi:10.1016/S0002-9440(10)65149-8 PubMedCentralPubMedCrossRef

13.

Fogar P, Sperti C, Basso D, Sanzari MC, Greco E, Davoli C et al (2006) Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 32:22–28. doi:10.1097/01.mpa.0000188305.90290.50 PubMedCrossRef

14.

Miglani RK, Bhateja N, Bhat RS, Kumar KVA (2013) Diagnostic role of platelet Lymphocyte Ratio (PLR) in pancreatic head masses. Indian J Surg 75(1):4–9. doi:10.1007/s12262-012-0443-6 PubMedCentralPubMedCrossRef

15.

Smith RA, Bosonnet L, Ghaneh P, Sutton R, Evans J, Healey P et al (2008) The platelet–lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer. Surgery 143(5):658–666. doi:10.1016/j.surg.2007.12.014 PubMedCrossRef

16.

Suzuki K, Aiura K, Kitagou M, Hoshimoto S, Takahashi S, Ueda M et al (2004) Platelet counts closely correlate with the disease-free survival interval of pancreatic cancer patients. Hepatogastroenterology 51:847–853PubMed

17.

Brown KM, Domin C, Aranha GV, Yong S, Shoup M et al (2005) Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg 189:278–282. doi:10.1016/j.amjsurg.2004.11.014 PubMedCrossRef

18.

Sata N, Koizumi M, Nagai H (2007) Alcoholic pancreatopathy: a proposed new diagnostic category representing the preclinical stage of alcoholic pancreatic injury. J Gastroenterol 42(Suppl 17):131–134. doi:10.1007/s00535-006-1936-5 PubMedCrossRef

19.

Augustine P, Ramesh H (1992) Is tropical pancreatitis premalignant? Am J Gastroenterol 87:1005–1008. doi:10.1007/s00535-006-1936-5 PubMed

20.

Lesniak RJ, Hohenwalter MD, Taylor AJ (2002) Spectrum of causes of pancreatic calcifications. Am J Roentgenol 178:79–86. doi:10.2214/ajr.178.1.1780079 CrossRef

21.

Kwon HC, Kim SH, Oh SY, Lee S, Lee JH et al (2012) Clinical significance of preoperative neutrophil–lymphocyte versus platelet–lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 17:216–222. doi:10.3109/1354750X.2012.656705 PubMedCrossRef

22.

Asher V, Lee J, Innamaa A, Bali A (2011) Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol 13:499–503. doi:10.1007/s12094-011-0687-9 PubMedCrossRef

23.

Azab B, Shah N, Radbel J, Tan P, Bhatt V (2013) Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol 30:432. doi:10.1007/s12032-012-0432-4 PubMedCrossRef

24.

Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T (2012) Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol 23:265–273. doi:10.3802/jgo.2012.23.4.265 PubMedCentralPubMedCrossRef

25.

Seretis C, Seretis F, Lagoudianakis E, Politou M, Gemenetzis G et al (2012) Enhancing the accuracy of platelet to lymphocyte ratio after adjustment for large platelet count: a pilot study in breast cancer patients. Int J Surg Oncol 2012:653608. doi:10.1155/2012/653608 PubMedCentralPubMed

26.

Liu H, Wu Y, Wang Z, Yao Y, Chen F et al (2013) Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer. J Thorac Dis 5(6):783–789. doi:10.3978/j.issn.2072-1439.2013.12.34 PubMedCentralPubMed

Title: Preoperative Platelet–Lymphocyte Ratio Augments CA 19-9 as a Predictor of Malignancy in Chronic Calcific Pancreatitis
Authors: Ashwin Rammohan
Sathya D. Cherukuri
Ravichandran Palaniappan
Senthil Kumar Perumal
Jeswanth Sathyanesan
Manoharan Govindan
Publication date: 01-09-2015
Publisher: Springer International Publishing
Published in: World Journal of Surgery / Issue 9/2015
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-015-3087-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Preoperative Platelet–Lymphocyte Ratio Augments CA 19-9 as a Predictor of Malignancy in Chronic Calcific Pancreatitis

Abstract

Introduction

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2015

A Novel Technique of Anti-reflux Esophagogastrostomy Following Left Thoracoabdominal Esophagectomy for Carcinoma of the Esophagogastric Junction

National Comprehensive Cancer Network Resectability Status for Pancreatic Carcinoma Predicts Overall Survival

Risk-Directed Algorithms for Pediatric PTC Patients: Is It Time?

Prehospital and Emergency Care: Updates from the Disease Control Priorities, Version 3

Naso-enteric Tube Placement: A Review of Methods to Confirm Tip Location, Global Applicability and Requirements

Commentary on “Preoperative Sarcopenia Negatively Impacts Postoperative Outcomes Following Major Hepatectomy with Extrahepatic Bile Duct Resection”